ReviewBiomedicines2022
Pharmacological Optimization of PSMA-Based Radioligand Therapy.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07635524 (A Two Center Phase 2 Trial of 61Cu-noDAGa-PSMA I&T), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Two Center Phase 2 Trial of 61Cu-noDAGa-PSMA I&T (61Cu-NU101) for Patients With Prostate Cancer
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Efficacy, safety, and quality of life outcomes of [International urology and nephrology · 2026Review
- A Spatiotemporal Image-Guided Model of Radiopharmaceutical Transport in Heterogeneous Vasculature Prostate Tumor: A Computational Analysis of Key Parameters in Lutetium-177 PSMA Therapy.Annals of biomedical engineering · 2026Article
- Assessing PSMA Receptor Availability Using 68Ga-PSMA-11 PET/CT Following 177Lu-PSMA-617 Therapy Administration.Clinical nuclear medicine · 2026Article
- A phase II study evaluating pharmacokinetics and dosimetry ofEJNMMI research · 2026Article
- Design and characterization of a novel prostate-specific membrane antigen-targeted radioligand modified with a fatty acid albumin binder for optimized circulation half-life.EJNMMI radiopharmacy and chemistry · 2025Article
- Paving the way for future PSMA inhibitors: insights from comparative preclinical evaluations of structure modifications.EJNMMI radiopharmacy and chemistry · 2025Article
- Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Dual-Labeled Small Peptides in Cancer Imaging and Fluorescence-Guided Surgery: Progress and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2025Review
- PSMA-based theranostics in diagnosing and treating prostate cancer in the Asian male population: a narrative review.Frontiers in oncology · 2025Review
- Standardized template for clinical reporting of PSMA PET/CT scans.European journal of nuclear medicine and molecular imaging · 2024Article
- Searching for Protein Off-Targets of Prostate-Specific Membrane Antigen-Targeting Radioligands in the Salivary Glands.Cancer biotherapy & radiopharmaceuticals · 2024Article
- From Despair to Hope: First Arabic Experience ofCancers · 2024Article
- Quantification of biochemical PSA dynamics after radioligand therapy with [EJNMMI physics · 2024Article
- Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.International journal of molecular sciences · 2024Article
- Predicting the effect of different folate doses on [EJNMMI research · 2023Article
- Article
- Imageological/Structural Study regarding the Improved Pharmacokinetics byPharmaceuticals (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is the most common malignancy in men of middle and older age. The standard treatment strategy for PCa ranges from active surveillance in low-grade, localized PCa to radical prostatectomy, external beam radiation therapy, hormonal treatment and chemotherapy. Recently, the use of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) for metastatic castration-resistant PCa has been approved. PSMA is predominantly, but not exclusively, expressed on PCa cells. Because of its high expression in PCa, PSMA is a promising target for diagnostics and therapy. To understand the currently used RLT, knowledge about pharmacokinetics (PK) and pharmacodynamics (PD) of the PSMA ligand and the PSMA protein itself is crucial. PK and PD properties of the ligand and its target determine the duration and extent of the effect. Knowledge on the concentration-time profile, the target affinity and target abundance may help to predict the effect of RLT. Increased specific binding of radioligands to PSMA on PCa cells may be associated with better treatment response, where nonspecific binding may increase the risk of toxicity in healthy organs. Optimization of the radioligand, as well as synergistic effects of concomitant agents and an improved dosing strategy, may lead to more individualized treatment and better overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.